S&P Futures
3,812.25 -15.00 (-0.39%) Dow Futures
30,948.00 -113.00 (-0.36%) Nasdaq Futures
11,560.25 -51.00 (-0.44%) Russell 2000 Futures
1,719.30 -9.20 (-0.53%) Crude Oil
110.30 +1.87 (+1.72%) Gold
1,807.40 +5.90 (+0.33%)
Delcath Systems, Inc. (DCTH)
Chart Events
Performance Outlook
| Previous Close | 3.9900 |
| Open | 3.9300 |
| Bid | 3.5700 x 1400 |
| Ask | 4.8800 x 800 |
| Day's Range | 3.9000 - 4.0000 |
| 52 Week Range | 3.4900 - 13.2500 |
| Volume | |
| Avg. Volume | 29,650 |
| Market Cap | 28.69M |
| Beta (5Y Monthly) | 0.55 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Benzinga
Delcath Systems Stock Jumps After Data Update From Eye Cancer Trials At ASCO Meeting
Delcath Systems Inc (NASDAQ: DCTH) announced further details regarding presentations relating to its proprietary percutaneous hepatic perfusion (PHP) system. The CHOPIN trial assessed ipilimumab plus nivolumab (IPI+NIVO) combined with Delcath's proprietary liver-targeted PHP treatment in metastatic uveal melanoma patients. The poster reports a Best Overall Response of 1 complete response, five partial responses, and one stable disease accounting for an Objective Response Rate of 85.7%. Related:
- Simply Wall St.
Is Delcath Systems (NASDAQ:DCTH) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
- Benzinga
Delcath's Chemosat Hepatic Delivery System Shows Overall Response Rate Of 60.5% In Eye Cancer That Spreads To Liver
Delcath Systems Inc's (NASDAQ: DCTH) single-institution retrospective study data on CHEMOSAT Hepatic Delivery System for liver dominant metastatic uveal melanoma (mUM) were published in the journal Melanoma Research. 41 of 81 (50.6%) patients had received other treatments, either systemic or liver-directed, before percutaneous hepatic perfusion (PHP) treatment. 250 PHP procedures were performed in 81 patients. The Company's PHP system is designed to administer high-dose chemotherapy to the liver
